Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NovaDel may seek bankruptcy protection, even as it regains rights to anti-emetic

This article was originally published in Scrip

Executive Summary

The US specialty company NovaDel Pharma announced on 18 January that it may not have adequate cash to continue operation beyond the end of January 2012. Two days later, it said it terminated certain licence agreements with Talon Therapeutics and Par for its oral spray formulation of the off-patent anti-emetic ondansetron, Zensana, in the US and Canada. The investigational candidate was in preclinical development.

Topics

Related Companies

UsernamePublicRestriction

Register

SC016024

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel